Docetaxel - Meridian Lab
Alternative Names: Captisol-enabled® docetaxel; ML-061Latest Information Update: 01 Dec 2022
Price :
$50 *
At a glance
- Originator Meridian Lab
- Class Antineoplastics; Small molecules; Taxanes
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Registered Breast cancer; Gastric cancer; Non-small cell lung cancer; Prostate cancer; Squamous cell cancer
Most Recent Events
- 22 Nov 2022 Registered for Breast cancer (Combination therapy, Adjuvant therapy) in USA (IV)
- 22 Nov 2022 Registered for Breast cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV)
- 22 Nov 2022 Registered for Gastric cancer (Combination therapy, First-line therapy, Late-stage disease) in USA (IV)